Featuring the Latest in Stroke Research and Care: The Paper of the Month

The Paper of the Month initiative is brought to you by the Council of Fellows to highlight interesting and relevant papers published by ESO members or with special relevance to Europe.

Papers will be suggested by members of the Paper of the Month (PoM) Working Group. All ESO members can nominate a paper by sending it directly to esoinfo@eso-stroke.org. Please note, you cannot nominate a paper in which you are a named author.

October 2026

Tenecteplase versus standard care for minor ischaemic stroke according to the baseline occlusion status in TEMPO-2 trial

“The optimal management of minor ischaemic stroke remains a challenging issue in acute stroke care, particularly when vascular imaging reveals an intracranial arterial occlusion. Although these patients may be at increased risk of neurological deterioration, whether they benefit from intravenous thrombolysis remains uncertain.

In this secondary analysis of the TEMPO-2 trial, Räty and colleagues investigated whether baseline vessel occlusion status influenced the effectiveness of tenecteplase compared with non-thrombolytic standard care. Among 881 patients with minor ischaemic stroke (NIHSS ≤5), no improvement in 90-day functional outcomes was observed with tenecteplase across subgroups with complete occlusion, near occlusion, or no visible occlusion. Importantly, higher mortality and more serious adverse events were observed with tenecteplase in the near-occlusion subgroup, although these findings require cautious interpretation.

These results extend the findings of the original TEMPO-2 trial and challenge the assumption that the presence of an intracranial occlusion alone justifies thrombolysis in patients with minor stroke. While the exploratory nature of this analysis limits definitive conclusions, the findings highlight the importance of carefully balancing treatment benefits and risks. The key clinical message is that vascular imaging findings alone may not be sufficient to guide thrombolytic treatment decisions in minor ischaemic stroke. Further research is needed to identify which patients may benefit from reperfusion therapy, supporting a more individualised approach to acute stroke management.“

Räty S, Strbian D, Singh N, Vatanpour S, Tomppo L, Ganesh A, Campbell BC, Parsons MW, Hill MD, Coutts SB. Tenecteplase versus standard care for minor ischaemic stroke according to the baseline occlusion status in TEMPO-2 trial. European Stroke Journal. 2026 Sep;11(9):aakag111. https://doi.org/10.1093/esj/aakag111

September 2026

Implementation of an AI-supported decision-making tool in a high-volume stroke system with routine perfusion imaging

“Karlsson and colleagues evaluated the regional implementation of Brainomix 360 Stroke in a high-volume Swedish stroke system including one comprehensive stroke centre and six primary stroke centres. The study included 970 consecutive patients treated with endovascular thrombectomy and compared workflow before, during, and after implementation of the AI-supported imaging tool. The key finding was a substantial reduction in adjusted CT-to-puncture time, from 47 minutes before implementation to 35 minutes in the established period. The greatest gains were observed at primary stroke centres, where CT-to-perfusion-map availability also improved significantly. Importantly, these workflow improvements were not accompanied by significant differences in early neurological improvement or 90-day functional outcome. This study provides useful real-world evidence that AI-supported imaging can improve efficiency across regional stroke networks, particularly at referring centres. It also underlines that the value of AI may lie not only in image interpretation, but in supporting faster and more coordinated decision-making across the entire stroke pathway.“

Karlsson A, Cadeborn E, Woock M, Allardt A, Jood K, Björkman-Burtscher I, Rentzos A. Implementation of an AI-supported decision-making tool in a high-volume stroke system with routine perfusion imaging. European Stroke Journal. 2026 Aug;11(8):aakag098. https://doi.org/10.1093/esj/aakag098

August 2026

Trends in mortality and disability from ischaemic stroke in Europe, 1990-2023

“Brigo and colleagues provide a valuable overview of trends in ischaemic stroke burden across Europe from 1990 to 2023. While age-standardised mortality and DALYs declined in all countries, progress was uneven, with slower improvements in parts of Eastern and Southeastern Europe.

Importantly, reductions in stroke burden were driven mainly by lower premature mortality, whereas disability declined less markedly. This highlights an emerging challenge for European stroke care: as more patients survive, greater attention is needed on rehabilitation, long-term recovery and secondary prevention.

Despite the limitations inherent to modelled GBD estimates, the study clearly shows that major geographical inequalities persist. The next challenge is therefore not only to reduce stroke mortality, but also to ensure better functional outcomes and more equitable stroke care across Europe.“

Brigo F, Zini A, Groppa S, Winter Y, Lochner P. Trends in mortality and disability from ischaemic stroke in Europe, 1990-2023. European Stroke Journal. 2026 Jul;11(7):aakag082.
https://doi.org/10.1093/esj/aakag082

July 2026

Regional inequities in acute stroke care in Norway: a national benchmark for the “stroke action plan for Europe” implementation

“Despite its universal healthcare system, Norway continues to face significant regional disparities in acute stroke care. In this important national survey, Kurz and colleagues provide a valuable benchmark of Norwegian stroke services against the goals of the Stroke Action Plan for Europe (SAP-E), demonstrating that universal healthcare does not necessarily guarantee equitable access to advanced stroke treatment.

While intravenous thrombolysis is available nationwide, access to extended-window thrombolysis, endovascular thrombectomy, advanced imaging, and well-organized regional stroke networks varies considerably across the country. By systematically evaluating infrastructure, imaging capabilities, reperfusion pathways, and network organization, the authors identify the structural factors that underpin equitable stroke care.

The implications extend well beyond Norway. As Europe progresses with SAP-E implementation, this study offers a practical framework for assessing national stroke services and highlights that improving outcomes requires not only technological advances but also coordinated regional networks and standardized referral pathways. The Norwegian experience provides an important reminder that geography should never determine access to evidence-based stroke care.“

Kurz MW, de la Fuente Sanz E, Alo I, Alo I, Rezai M, Kurz KD, Roaldsen MB, Eltoft A, Ofte HK, Ildstad F, Fromm A. Regional inequities in acute stroke care in Norway: a national benchmark for the “stroke action plan for Europe” implementation. European Stroke Journal. 2026 Jun;11(6):aakag072.
https://doi.org/10.1093/esj/aakag072

June 2026

Endovascular treatment for medium or distal vessel occlusion stroke (DISTAL): 12-month outcomes of a multicentre, open-label, randomised trial

“The optimal management of medium and distal vessel occlusion (DMVO) stroke remains one of the most challenging questions in contemporary stroke medicine. While thrombectomy has become standard of care for large vessel occlusions, its role in more distal occlusions remains uncertain. Against this backdrop, Fischer and colleagues present the 12-month outcomes of the DISTAL trial, providing valuable insight into the longer-term consequences of treatment decisions in this patient population.

The importance of this analysis lies not only in its results but also in its timing. Following several recent randomized trials that have tempered enthusiasm for routine thrombectomy in DMVO stroke, the focus has shifted from whether these occlusions can be treated to which patients are most likely to benefit. The DISTAL trial contributes to this discussion by extending follow-up beyond the traditional 90-day endpoint and examining whether early treatment effects translate into sustained functional outcomes. The study highlights the complexity of DMVO stroke, where clinical deficits, infarct patterns, collateral status, and procedural risks may vary substantially. These factors make a uniform treatment approach unlikely to succeed. Instead, the findings reinforce the growing view that individualized patient selection remains central to decision-making. Importantly, the trial reminds us that the future of DMVO treatment is unlikely to be determined by a single study. Rather, it will emerge from integrating evidence across randomized trials, imaging studies, and subgroup analyses.

In this evolving landscape, the DISTAL trial provides an important benchmark and further refines our understanding of where thrombectomy may offer meaningful benefit. As stroke intervention continues to move into smaller and more distal vessels, the key question is no longer whether these arteries can be reached, but whether intervention improves outcomes that matter to patients. The long-term results from DISTAL bring us one step closer to that answer.“

Fischer U, Brehm A, Ribo M, Rizzo F, Strbian D, Räty S, Arenillas JF, Martínez-Galdámez M, Hajdu SD, Michel P, Gralla J. Endovascular treatment for medium or distal vessel occlusion stroke (DISTAL): 12-month outcomes of a multicentre, open-label, randomised trial. The Lancet Neurology. 2026 Jun 1;25(6):571-80.
https://doi.org/10.1016/S1474-4422(26)00169-9

May 2026

One-year functional outcome of the Flying Intervention Team versus patient interhospital transfer in acute ischaemic stroke

“The study by Hubert and colleagues addresses an important challenge in modern stroke care: Improving access to mechanical thrombectomy for patients treated far from comprehensive stroke centers. By comparing one-year functional outcomes between the Flying Intervention Team (FIT) model and conventional interhospital patient transfer, the authors evaluate an innovative approach to stroke network organization.

The FIT concept, in which the neurointerventional team travels to the patient instead of transferring the patient to the intervention center, may help reduce treatment delays and improve long-term outcomes, particularly in remote regions. A notable strength of the study is the assessment of one-year outcomes, providing insight beyond the standard 90-day follow-up commonly used in stroke research.

This work contributes to the ongoing discussion regarding optimal thrombectomy pathways and highlights the importance of efficient stroke systems of care. Although implementation of FIT models may depend on local resources and infrastructure, the study supports continued innovation aimed at improving access to advanced stroke treatment and long-term patient outcomes.”

Hubert ND, Holler M, Wernsdorf SR, Herdegen S, Maegerlein C, Wiestler H, Esterl-Pfäffl L, Dietrich D, Witton-Davies T, Heinrich I, Mpotsaris A. One-year functional outcome of the Flying Intervention Team versus patient interhospital transfer in acute ischaemic stroke. European Stroke Journal. 2026 Apr;11(4):aakag025.
https://doi.org/10.1093/esj/aakag025

April 2026

Stroke Action Plan for Europe 2018–2030 (SAP-E): mid-term review and update

“The mid-term review of the Stroke Action Plan for Europe (SAP-E) provides a timely and critical appraisal of progress toward improving stroke care across Europe. While the initiative has successfully raised awareness and fostered policy engagement, the report highlights a persistent gap between strategic goals and real-world implementation.
Encouragingly, several countries have demonstrated measurable advances in acute stroke care, including increased access to reperfusion therapies and improved organization of stroke services. However, progress remains uneven, with substantial disparities between Western and Eastern Europe in infrastructure, workforce capacity, and access to specialized care.
A key message of this update is the need to transition from planning to accountability. The authors emphasize the importance of robust monitoring systems, standardized data collection, and national-level ownership to ensure that SAP-E targets translate into tangible outcomes. Particularly concerning is the slower-than-expected improvement in primary prevention and long-term rehabilitation, which continue to lag behind acute care advancements.
The review also underscores emerging priorities, including digital health integration, strengthening stroke networks, and addressing demographic pressures associated with aging populations. Without intensified efforts, the ambitious goals set for 2030 – such as reducing stroke incidence and improving functional outcomes – may remain unmet.
In summary, this mid-term evaluation serves as both a progress report and a call to action. Achieving SAP-E objectives will require sustained political commitment, equitable resource allocation, and stronger cross-country collaboration to reduce disparities and improve stroke care for all European citizens.
“

Christensen H, Pezzella FR, Roaldsen MB, Tomek A, Wilkie A, Christensen L, Dichgans M, Drummond A, Laatikainen T, Molina CA, Sunnerhagen KS. Stroke Action Plan for Europe 2018–2030 (SAP-E): mid-term review and update. European stroke journal. 2026 Jan;11(1):aakaf026. https://doi.org/10.1093/esj/aakaf026

March 2026

Early versus delayed DOAC after ischaemic stroke in atrial fibrillation: 1-year outcomes in the TIMING study and in concurrent practice.

“Optimal timing of anticoagulation after atrial-fibrillation–related ischaemic stroke remains a critical clinical question, balancing the risk of early recurrent embolism against the risk of haemorrhagic transformation. The registry-based randomized TIMING trial previously demonstrated that early initiation of direct oral anticoagulants (≤4 days) was non-inferior to delayed initiation (5–10 days) for preventing recurrent events at 90 days.

In this new analysis, Fasth and colleagues report 1-year outcomes from the TIMING trial together with data from contemporaneous clinical practice, providing valuable longer-term evidence. The results confirm that early DOAC initiation remains safe and effective over 12 months, with no increase in symptomatic intracerebral haemorrhage and similar or numerically lower rates of recurrent ischaemic stroke, mortality, and major cardiovascular events compared with delayed initiation.

Importantly, the findings reinforce growing evidence from recent randomized trials (including ELAN and OPTIMAS) suggesting that earlier anticoagulation after AF-related stroke is a reasonable strategy in selected patients, challenging the historically conservative “1-3-6-12 day rule.”

From a clinical perspective, the TIMING long-term data provide reassurance that early DOAC initiation is not only safe in the acute phase but also maintains favourable outcomes over time. These results support a shift toward earlier secondary prevention strategies, while still emphasizing individualized decision-making based on stroke severity, infarct size, and bleeding risk.”

Fasth O, Oldgren J, Ghukasyan Lakic T, Hijazi Z, Norrving B, Wester P, Åsberg S. Early versus delayed DOAC after ischaemic stroke in atrial fibrillation: 1-year outcomes in the TIMING study and in concurrent practice. European Stroke Journal. 2026 Jan;11(2):aakag010. doi: https://doi.org/10.1093/esj/aakag010

February 2026

Recurrent Cervical Artery Dissection Prevalence and Predictors: A Secondary Analysis of the STOP-CAD Study.

“Cervical artery dissection (CeAD) is a major cause of stroke in younger adults, yet data on recurrence risk remain limited. In a recent secondary analysis of the international STOP-CAD cohort, Marto and colleagues provide contemporary estimates of recurrent CeAD prevalence and explore clinical predictors of recurrence. Recurrent dissection was found to be uncommon but not negligible, confirming that most patients experience a favourable course after the initial event. Importantly, recurrence risk was not uniform across the cohort. Certain clinical and imaging characteristics appeared to cluster in patients with subsequent events, suggesting that underlying vascular vulnerability may differ between individuals. These findings have practical implications for patient counselling and follow-up. While routine long-term surveillance may not be necessary for all patients, identifying higher-risk phenotypes could support a more individualised approach to monitoring and secondary prevention. Overall, this STOP-CAD analysis strengthens the evidence that recurrent CeAD is rare but clinically relevant and highlights the importance of large international registries in refining risk stratification for uncommon stroke mechanisms.”

Marto JP, Shu L, Wu E, Mendel DM, Heldner MR, Kaufmann JE, Leker RR, Zedde M, Nehme A, Muppa J, Aguiar de Sousa D. Recurrent Cervical Artery Dissection Prevalence and Predictors: A Secondary Analysis of the STOP-CAD Study. Stroke, 2026 January 12, doi: https://doi.org/10.1161/STROKEAHA.125.053299

January 2026

Thrombectomy for Medium-Sized Cerebral Vessel Occlusion: Size Does Matter

“This single-centre observational study addresses a clinically relevant and underexplored determinant of outcomes in endovascular thrombectomy (EVT) for medium vessel occlusions (MeVO): the mismatch between thrombectomy device size and target vessel diameter. While recent randomised trials have raised concerns about the overall benefit of EVT in MeVO, this analysis provides a mechanistic perspective that may help explain observed neutrality or futility.

The authors demonstrate that using thrombectomy devices substantially larger than the occluded M2 segment (>20% oversizing) is independently associated with higher rates of symptomatic intracranial haemorrhage and futile clinical outcomes. These findings suggest that procedural factors – rather than patient selection alone – may critically influence MeVO EVT safety and effectiveness. The graded increase in harm with increasing device-to-vessel size ratio strengthens the biological plausibility of vessel injury and distal endothelial damage as contributing mechanisms.

Although limited by its retrospective design and single-centre setting, the study highlights the importance of tailoring device choice to vessel anatomy in MeVO thrombectomy. It underscores the need for dedicated MeVO-specific devices, refined procedural strategies, and careful interpretation of trial results where device selection was heterogeneous. Future randomised trials and guideline recommendations should explicitly account for device-to-vessel size matching to optimise outcomes and minimise harm in this patient population.”

Virtanen P, Räty S, Tomppo L, Brandstack N, Peltola E, Kokkonen T, Sillanpää M, Strbian D, Thrombectomy for medium-sized cerebral vessel occlusion: Size does matter, European Stroke Journal, 11, (1), January 2026, doi: 10.1093/esj/23969873251376862

Members of the PoM Working Group

  • Anita Arsovska (Chair)
  • Freimuth Brunner
  • Stefano Ricci
  • Vladimir Nosal
  • Marialuisa Zedde
  • Ilko Meier

Archive

“In this large real-life study, authors found that rates of parenchymal haemathoma (PH) and any intracerebral haemorrhage (ICH) after intravenous thrombolysis were 9.5% and 39.4%, respectively. In particular, older age, male gender, history of hypertension, higher baseline NIHSS and higher admission blood glucose levels were significantly associated with an increased risk of PH. These findings can help to identify patients presenting with an increased risk of ICH.”

Marnat G, Gerschenfeld G, Olindo S, Sibon I, Seners P, Clarençon F, Smadja D, Chausson N, Ben Hassen W, Piotin M, Caroff J. Incidence and predictors of intracranial hemorrhage after intravenous thrombolysis with tenecteplase. European Stroke Journal. 2024 May doi/10.1177/23969873241253660

“The authors concluded that although treatment and outcome parameters seem to be in favor of men, most can be explained by older age, poorer prestroke independence, higher stroke severity, and more large vessel occlusion in women. Sex was not independently associated with worse 90-day functional outcome in women.”

Westphal LP, Rüttener L, Gasser T, Luft AR, Held U, Wegener S. Sex Differences in the Pre-and In-Hospital Setting of Patients With Stroke Are Driven by Higher Age and Stroke Severity. Stroke. 2025 Feb; https://doi.org/10.1161/STROKEAHA.124.048303

“The rate of recurrent thrombosis and major bleeding did not differ between patients with CVT treated with DOACs versus VKAs. This study adds to the increasing evidence that DOACs are a reasonable treatment option for CVT alongside VKAs.“

van de Munckhof A, van Kammen MS, Tatlisumak T, Krzywicka K, Aaron S, Antochi F, Arauz A, Barboza MA, Conforto AB, Contreras DG, Heldner MR, Hernández-Pérez M, Hiltunen S, Ji X, Kam W, Kleinig TJ, Kristoffersen ES, Leker RR, Lemmens R, Poli S, Wasay M, Wu T, Yeşilot N, Chen J, Cotelli MS, Demeestere J, Duan J, Ergin N, Freitas TE, Gomes A, den Hertog HM, Lindgren E, Martinez-Majander N, Metanis I, Miraclin A, Rani LJ, Reddy YM, Saleem S, Scutelnic A, Shanmugasundaram S, van den Wijngaard IR, Gençdal IY, van Eekelen R, Vellema J, Arnold M, Neto L, Middeldorp S, de Sousa DA, Jood K, Putaala J, Ferro JM, Coutinho JM; DOAC-CVT investigators. Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study. Lancet Neurol. 2025 Mar; 24(3): 199-207. doi: 10.1016/S1474-4422(24)00519-2. PMID: 39986309.

“The authors concluded that in patients presenting with an anterior circulation tandem occlusion secondary to cervical artery dissection, emergent stenting was associated with a higher likelihood of successful intracranial recanalisation, but not improved functional outcomes or increased symptomatic intracranial haemorrhage. It remains unclear whether emergent stenting led to successful intracranial recanalisation or patients with successful intracranial recanalisation were more likely to be stented.”

Sousa JA, Rodrigo-Gisbert M, Shu L, Luo A, Xiao H, Mahmoud NA, Shah A, Oliveira Santos AL, Moore M, Mandel DM, Heldner MR. Emergent Carotid Stenting During Thrombectomy in Tandem Occlusions Secondary to Dissection: A STOP-CAD Secondary Study. Stroke. 2025 Apr; 56(4): 808-817. doi.org/10.1161/STROKEAHA.124.048295

“The 2-year interim analysis of ECST-2 found no evidence for a benefit of revascularisation in addition to OMT for patients with symptomatic and asymptomatic carotid stenosis of 50% or greater, with a 5-year predicted stroke risk of less than 20% (as assessed by the CAR score), in the first 2 years following the procedure. The risk of stroke in patients treated with OMT alone was substantially lower than recorded with best medical treatment in previous carotid stenosis trials. Further follow-up of ECST-2 up to 5 years from randomisation, and data from other trials, will be needed to confirm these findings. In the meantime, these results support treating patients with asymptomatic and low or intermediate risk symptomatic carotid stenosis with OMT alone. Applying individualised risk assessment could result in a reduction in revascularisation procedures and substantial cost savings in the future. Identifying patients with carotid stenosis who are at high risk of future stroke, who might benefit from revascularisation, should also be a goal of future research.”

Donners SJ, van Velzen TJ, Cheng SF, Gregson J, Hazewinkel AD, Pizzini FB, Emmer BJ, Simister R, Richards T, Lyrer PA and Maurer M. Optimised medical therapy alone versus optimised medical therapy plus revascularisation for asymptomatic or low-to-intermediate risk symptomatic carotid stenosis (ECST-2): 2-year interim results of a multicentre randomised trial. Lancet Neurol. 2025; 24(5): 389-399. doi.org/10.1016/S1474-4422(25)00107-3

“Randomised assessment of EVT in patients with large strokes in 6 clinical trials across 4 continents has yielded strong and consistent results, cementing the utility of reperfusion, even in those with substantial volumes of irreversible ischemia. Most importantly, the benefits of reperfusion outweighed the potential harms of reperfusion-infarcted brain tissue across clinical and imaging characteristics, indicating the safety of the intervention. These results have challenged our fundamental understanding of the utility of neuroimaging in estimating ischemic changes and our dichotomous view of infarcted versus noninfarcted tissue. Further pooled analyses from these trials are planned and should clarify the role of endovascular thrombectomy in subgroups such as the elderly, those with the largest ischemic core in the late time window, and those without significant mismatch assessed by perfusion imaging.”

Sarraj A, Yoshimura S, Thomalla G, Huo X, Arquizan C, Yoo AJ, Morimoto T, Bendszus M, Lapergue B, Nguyen TN, Campbell BC. Mechanical Thrombectomy for Large Ischemic Stroke: A Critical Appraisal of Evidence From 6 Randomised Controlled Trials. Stroke. 2025 Jul. doi.org/10.1161/STROKEAHA.125.050402

“The authors presented the results of the SECRETO multi-center case-control study that enrolled 503 patient-control pairs aged 18–49 years with imaging-positive acute cryptogenic ischemic stroke and 1:1 matched stroke-free controls. Lupus anticoagulant (LA), anticardiolipin (aCL), and anti-beta2-glycoprotein I (aβ2GPI) IgG antibodies were assessed from blood samples taken at two time points (baseline and 12-weeks) from patients and at a single time point from controls.

At either time-point, compared to healthy controls, patients had more frequently positive aβ2GPI (patients 11.9% vs controls 2.0%, p < 0.001). There was no significant difference in the presence of positive LA between patients and controls. In the logistic regression model, at either time-point positive aB2GI and aCL were associated with CIS (odds ratio [OR] 11.22, 95% confidence interval [CI] 4.35–28.95 and OR 20.85, 95% CI 204–213.16, respectively). The frequency of patients with positive aβ2GPI or aCL increased from baseline to 12 weeks (p < 0.001), whereas frequency of positive LA results decreased (p < 0.001).

The authors concluded that positive aβ2GPI and aCL, but not LA, detected either shortly after stroke or after 12 weeks were associated with early-onset CIS. After the acute phase, frequencies of positive aβ2GPI and aCL increased, whereas LA showed a reverse trend.”

Jaakonmäki N, Helin T, Szanto T, Zedde M, Sarkanen T, Martinez-Majander N, Sinisalo J, Junttola U, Redfors P, von Sarnowski B, Waje-Andreassen U. Anti-beta2-glycoprotein I IgG antibodies are associated with early-onset cryptogenic ischemic stroke. European Stroke Journal. 2025 Apr 1. https://doi.org/10.1177/23969873251351207

“The authors performed a descriptive study of the cumulative costs incurred during 1-year follow-up of a cohort of patients with stroke in Catalonia (Spain) participating in a multicentre, population-based, cluster-randomised trial (RACECAT). Of the 567 patients included, 53% had ischaemic large vessel occlusion (LVO) stroke, 24% intracranial haemorrhage and 23% ischaemic non-LVO stroke. Mean cost per patient during the first year after stroke was €29,673 ± 28,632, and increased with degree of disability (mRS 0–2: €18,568 ± 12,244; mRS 3: €38,214 ± 28,172; mRS 4–5: €52,859 ± 36,383). Healthcare costs represented the highest proportion of total costs (63%; €18,724/patient) across all disability levels, with index hospitalisation being the highest (€12,319 ± 17,675); however, community care and patient/family costs represented over 40% of total cost in patients with higher disability levels.

These results are in line with other studies; the costs during the first year after stroke are high and increase with disability.”

Soler-Font M, Ribera A, Aznar-Lou I, Sánchez-Viñas A, Slof J, Vela E, Salvat-Plana M, Villa-García L, Serrano-Blanco A, Perez de la Osa N, Ribo M. Costs during the first year after stroke by degree of functional disability: A societal perspective. European Stroke Journal. 2025 Jun; 10(2): 513-23. doi: 10.1177/23969873241301904

“This study evaluated the 10-year budget impact of DOACs in France, focusing on reductions in strokes/SE, MB, and monitoring costs (INRt). A retrospective budget impact model from 2014 to 2023 compared scenarios with and without DOACs, using clinical and cost data from the NAXOS study. Over a 10-year horizon, the introduction of DOACs is estimated to have prevented 73,009 strokes, 97,234 major bleeding, and 19,567 stroke-related deaths among patients with NVAF. DOAC introduction increased treatment costs by €5.15 billion over 10 years, and reduced costs for strokes/SE (-€4.24 billion), MB (-€3.22 billion), and INRt (-€1.14 billion), leading to €3.45 billion of savings for National Insurance over 10 years, with apixaban contributing 55% of savings. The authors concluded that over 10 years, the introduction of DOACs in France has generated substantial savings in AF-related costs, highlighting their clinical and economic benefits and the importance for authorities to valorise the external effects of therapeutic innovations.”

Guilmet C, Lesage H, Cotté FE, Moreau R, Marant Micallef C, Née M, Guitard-Dehoux D, Belhassen M, Danchin N. Nationwide extrapolation of economic benefit of therapeutic innovation: a 10-year retrospective budget impact of direct oral anticoagulants introduction in France. Journal of Medical Economics. 2025 Dec 31;28(1):859-70. https://doi.org/10.1080/13696998.2025.2514381

“The authors aimed to determine whether the Edinburgh CT-only and CT-APOE diagnostic criteria for cerebral amyloid angiopathy-related lobar intracerebral haemorrhage are associated with recurrent intracerebral haemorrhage. They did a meta-analysis of individual patient data from cohort studies identified at the 2018 International cerebral amyloid angiopathy conference in Lille, France. In the primary two-stage meta-analysis of the CT-only criteria (562 patients from three European cohorts, median age 76 years , 282 [50%] female and 280 [50%] male), 69 patients had a recurrent intracerebral haemorrhage over 1381 person-years’ follow-up. The proportion with recurrent intracerebral haemorrhage during 5-year follow-up in the intermediate-risk and high-risk CT-only cerebral amyloid angiopathy criteria group was 48 (16%) of 307 patients compared with 21 (8%) of 255 patients in the low-risk group (adjusted sub-distribution hazard ratio 1·79, 95% CI 1·05–3·05, p=0·032). In the one-stage meta-analysis of the CT-only criteria (1620 patients with lobar intracerebral haemorrhage from eight cohorts, median age 73 years , 763 [47%] female and 857 [53%] male), 171 patients had a recurrent intracerebral haemorrhage over 3208 person-years’ follow-up. Cumulative 5-year incidence of recurrent intracerebral haemorrhage in the low-risk CT-only cerebral amyloid angiopathy criteria group was 45 (12%) of 727 patients compared with 54 (16%) of 513 patients in the intermediate-risk group (adjusted sub-distribution HR 1·68, 95% CI 1·21–2·32; p=0·0018), and 72 (26%) of 380 patients in the high-risk group (adjusted sub-distribution HR 2·97, 1·50–5·89, p=0·0018). They included six cohorts with 1021 eligible patients for the CT-APOE criteria. In the one-stage meta-analysis of the CT-APOE criteria (1006 patients, median age 71 years female and 529 [53%] male), 74 patients had a recurrent intracerebral haemorrhage over 1495 person-years’ follow-up. Cumulative 3-year incidence of recurrent intracerebral haemorrhage was 34 (15%) of 320 patients in the high-risk CT-APOE cerebral amyloid angiopathy criteria group versus 14 (8%) of 322 patients in the low-risk group (adjusted sub-distribution HR 2·22 [95% CI 1·36–3·61], p=0·0014). The authors concluded that the Edinburgh CT-only and CT-APOE diagnostic criteria for cerebral amyloid angiopathy-associated lobar intracerebral haemorrhage were associated with a greater incidence of recurrent intracerebral haemorrhage. These findings could aid personalised prediction and targeted secondary prevention in standard clinical practice where brain CT is available.”

Rodrigues MA, Seiffge D, Samarasekera N, Moullaali TJ, Wardlaw JM, Schreiber S, Behymer TP, Khandwala V, Stanton RJ, Vagal V and Woo D, Association between the Edinburgh CT and genetic diagnostic criteria for cerebral amyloid angiopathy-associated lobar intracerebral haemorrhage and recurrent intracerebral haemorrhage: an individual patient data meta-analysis. The Lancet Neurology. 2025; 24(10), pp. 828-839. https://doi.org/10.1016/S1474-4422(25)00285-6 

“Internal optic nerve sheath diameter (ONSDint) via transorbital ultrasound in 65 stroke patients and 30 controls was prospectively measured. ONSD was also measured on the initial CT or MRI. The primary endpoint of IH was a composite of clinical and radiological signs of brain swelling. Seven of 65 stroke patients (11%) developed IH. The initial sonographic ONSDint was significantly increased in patients who developed IH. The multivariable model identified an optimal predictive cut-off of ⩾5.51 mm, which predicted IH with a sensitivity of 85.7% and a specificity of 94.8%. In comparison, ONSD derived from initial neuroimaging was also a strong predictor, with an optimal cut-off of 6.80 mm yielding a sensitivity of 100% and a specificity of 91.1%, and showed superior predictive accuracy in the cross-validation (AUC 0.905 vs 0.687). These results align well with recent stroke literature that used similar standardised measurement techniques. The findings also highlight the distinct roles of different imaging modalities. While the initial CT/MRI provides a static measurement with high predictive power, the unique advantage of sonography is its bedside applicability, allowing for the crucial, non-invasive serial monitoring of ONSD as a dynamic marker of intracranial pressure changes. In conclusion: early ONSD assessment is a valuable predictor of IH after severe stroke. A sonographic ONSDint of ⩾5.51 mm identifies patients at high risk with excellent accuracy. While initial neuroimaging may offer superior predictive power, bedside sonography remains a crucial, repeatable tool for monitoring these critically ill patients.”

Baumgartner P, Zahn M, Handelsmann H-L, et al. Optic nerve sheath diameter for prediction of intracranial hypertension after ischemic sTrokE – The ONSITE study. European Stroke Journal. 2025; 0(0). doi:10.1177/23969873251379985

“The prevalence of depression was investigated 1 and 12 months after TIA in a population-based cohort (OXVASC ) from 2014 to 2020. Depression was related to risk factors (including infarction on brain imaging) and outcome (disability, quality of life, institutionalisation, recurrent events, and mortality) during 5-year follow-up. Of 519 patients (mean age, 70.5 [13.1]; female, 51.1%), 126 (24.3%) had depression after TIA, with a higher rate at 1 versus 12 months (99/20.7% versus 66/14.9%; P=0.022). Depression was independently associated with younger age (adjusted odds ratio/decade, 0.74 [95% CI, 0.60–0.90]), low baseline mood (4.06 [95% CI, 2.31–7.15]), past depression (1.81 [95% CI, 1.09–3.03]), multimorbidity (1.19 [95% CI, 1.02–1.39]), living alone (1.94 [95% CI, 1.14–3.32]), disability (3.53 [95% CI, 1.89–6.59]), and deprivation (1.28 [95% CI, 1.03–1.59]). After adjustment for confounders, depression did not predict risk of recurrent vascular events (adjusted hazard ratio , 1.42 [95% CI, 0.76–2.64]; P=0.27) but did predict increased 5-year all-cause mortality (aHR, 2.27 [95% CI, 1.21–4.27]; P=0.011), independently of acute lesions on brain imaging (aHR, 2.18 [95% CI, 1.09–4.34]; P=0.027), and particularly when persistent (present at 1- and 12-month follow-up; aHR, 4.58 [95% CI, 2.07–10.13]; P<0.001). Persistent depression was also independently associated with disability (adjusted odds ratio, 12.10 [95% CI, 6.18–23.7]; P<0.001) and institutionalisation (aHR, 5.83 [95% CI, 1.84–18.50]; P=0.003) within 5 years and with reduced quality of life (coefficient, −0.245; P<0.001). The authors concluded that depression is common early after TIA, independent of acute ischemia on brain imaging, and persistent depression is also strongly associated with adverse outcomes."

McColl AJ, Luengo-Fernandez R, Vaughan-Fowler ER, Downer MB, Pendlebury ST, Binney LE, Silver LE, Rothwell PM, Oxford Vascular Study. Prevalence, Predictors, and Prognosis of Depression After Transient Ischemic Attack: A Population-Based Study. Stroke; 2025 Dec 12. https://doi.org/10.1161/STROKEAHA.125.052251

COVID-19 Publications Relevant for Stroke Diagnosis and Management

COVID-19 Vaccination and Cerebrovascular Events

Additional Publications on COVID-19 and Stroke